Comparison

Biotinylated Mouse LRRC15 / LIB Protein, His,Avitag™ European Partner

Item no. LR5-M82E6-200ug
Manufacturer ACROBiosystems
Amount 200 ug
Category
Type Proteins Recombinant
Format Powder
Specific against Mouse
Host HEK293
Conjugate/Tag Biotin, HIS, Avi
Purity 95%
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib
Available
Manufacturers Category
Protein / MABSol® Biotin Labeled Proteins
Description
Biotinylated Mouse LRRC15, His, Avitag (LR5-M82E6) is expressed from human 293 cells (HEK293). It contains AA Tyr 22 - Gly 536 (Accession # Q80X72-1).
Molecule
LRRC15
Exp Region
Tyr 22 - Gly 536
Storage
-20℃
Shipping
RT
Stability
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Molecular Weight
61.2 kDa
Characteristics
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 61.2 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
1.0 EU per μg
Buffer
PBS, pH7.4
Background
LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 200 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close